ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
Ulrike Rauh(Centro de Pesquisas Oncológicas), Todd R. Golub(Broad Institute), Katrin Nowak‐Reppel(Nuvisan (Germany)), Georgios Kosmidis(Netherlands Consortium for Healthy Ageing), Matthias Ocker(Unknown), Karl Ziegelbauer(Almirall (Spain)), Virendar K. Kaushik(Broad Institute), Franziska Siegel(University of Bonn), James M. McFarland(Broad Institute), Sabine Pilari, Nicolas D. Werbeck(Bayer (Germany)), Kai Thede(Nuvisan (Germany)), Michael H. Serrano‐Wu(Broad Institute), Guo Wei(Broad Institute), Stefan Kaulfuß(Pfizer (Germany)), Stephan Menz(Bayer (Germany)), Brian Hubbard, Christopher T. Lemke(Broad Institute)
Cited by 1
Related Papers
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
|Proceedings of the National Academy of Sciences|2005|56.5k
Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring
|Science|1999|11.6k
PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes
|Nature Genetics|2003|10.6k
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Copper induces cell death by targeting lipoylated TCA cycle proteins
|Science|2022|4.6k